ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
Multimodality Imaging of Prostate Cancer.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- A multimodal fusion model integrating Vision Transformer, radiomics, and clinical features for predicting bone metastasis in prostate cancer.Frontiers in oncology · 2026Article
- Review
- Detection of Prostate Carcinoma in an Asymptomatic Individual Initiated by an Immunological Biopsy-A Case Report.Oncology research · 2026Article
- Three-dimensional spatial localization and volume estimation of prostate tumors usingEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Predictive impact of T2-MRI radiomics model on initial diagnosis of bone metastasis in prostate cancer patients.BMC medical imaging · 2025Article
- [Frontiers in medicine · 2025Article
- Article
- MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.Chemical & biomedical imaging · 2024Article
- Radiology of fibrosis part III: genitourinary system.Journal of translational medicine · 2024Review
- Application of next-generation imaging in biochemically recurrent prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).Oncology reports · 2024Review
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- MRI fat fraction imaging of nodal and bone metastases in prostate cancer.European radiology · 2023Article
- Review
- Intravoxel incoherent motion predicts positive surgical margins and Gleason score upgrading after radical prostatectomy for prostate cancer.La Radiologia medica · 2023Article
- Intra-Individual Comparison of Physiologic [Cancers · 2023Article
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors. In recent years, imaging has gained increasing importance in the detection, staging, posttreatment assessment, and detection of recurrence of prostate cancer. Several imaging modalities including conventional and functional methods are used in different clinical scenarios with their very own advantages and limitations. This continuing medical education article provides an overview of available imaging modalities currently in use for prostate cancer followed by a more specific section on the value of these different imaging modalities in distinct clinical scenarios, ranging from initial diagnosis to advanced, metastatic castration-resistant prostate cancer. In addition to established imaging indications, we will highlight some potential future applications of contemporary imaging modalities in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.